Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $8.7 million.

  • Vivos Therapeutics' Operating Expenses rose 7415.14% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 2076.24%. This contributed to the annual value of $20.2 million for FY2024, which is 2103.1% down from last year.
  • As of Q3 2025, Vivos Therapeutics' Operating Expenses stood at $8.7 million, which was up 7415.14% from $7.0 million recorded in Q2 2025.
  • Over the past 5 years, Vivos Therapeutics' Operating Expenses peaked at $10.5 million during Q4 2021, and registered a low of $4.6 million during Q2 2024.
  • Moreover, its 5-year median value for Operating Expenses was $7.0 million (2025), whereas its average is $7.1 million.
  • Per our database at Business Quant, Vivos Therapeutics' Operating Expenses soared by 9742.56% in 2021 and then crashed by 3183.6% in 2023.
  • Over the past 5 years, Vivos Therapeutics' Operating Expenses (Quarter) stood at $10.5 million in 2021, then fell by 19.69% to $8.4 million in 2022, then dropped by 26.34% to $6.2 million in 2023, then dropped by 21.2% to $4.9 million in 2024, then skyrocketed by 76.85% to $8.7 million in 2025.
  • Its Operating Expenses stands at $8.7 million for Q3 2025, versus $7.0 million for Q2 2025 and $5.4 million for Q1 2025.